Immunic, Inc. (NASDAQ:IMUX) announced that Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present today previously unpublished data regarding the company’s lead program, IMU-838, at the GI Inflammatory Diseases Summit (GIIDS) in Boston. The presentation, entitled, “IMU-838 in Clinical Phase 2 – New Selective Oral Treatment for IBD,” will take place at 3:30 pm ET. IMU-838, currently in phase 2 clinical development for the treatment of ulcerative colitis (UC) and relapsing-remitting multiple sclerosis (RRMS), is an orally available, next-generation selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase (DHODH).
Immunic, Inc. (NASDAQ:IMUX), a Healthcare sector firm, traded 1.54 Million shares in last trading session with closing price of $17.75 per share. Stock value has moved between $6.04 – 355 in last one year. Analyst’s mean target price for Immunic, Inc. (NASDAQ:IMUX) is $50.00 while analysts mean recommendation is 1.00. IMUX EPS growth this year is 25.10%.
On last trading day, Krystal Biotech, Inc. (NASDAQ:KRYS) shares closed at $41.20 per share. KRYS market capitalization is 590.40. Analyst’s mean target price for Krystal Biotech, Inc. (NASDAQ:KRYS) is $45.50 whereas analysts mean recommendation is 1.60. Its weekly performance is 43.55% while year to date (YTD) performance is 98.27%.
In last session Minerva Neurosciences, Inc. (NASDAQ:NERV) traded 27.76 Million shares and was closed at $5.93. Analyst’s mean target price for NERV is $19.75 while analysts mean recommendation is 1.50. Company is -54.21% away from its 52 week high and is moving 45.70% ahead of its 52 week low. NERV return on assets is -36.90%. Minerva Neurosciences, Inc. (NASDAQ:NERV) quarterly performance is -23.58%.
VBI Vaccines Inc. (NASDAQ:VBIV), a Healthcare sector firm, traded 7.59 Million shares on last trading day with closing price of $1.29 per share. Stock value has moved between $0.58 – 3.23 in last one year. Analyst’s mean target price for VBI Vaccines Inc. (NASDAQ:VBIV) is $8.25 while analysts mean recommendation is 1.50.
